One2Treat
One2Treat is a Belgium-based tech company specializing in integrating patient perspectives into pharmaceutical R&D decision-making.
Profile
Develops software to incorporate patient preferences into clinical trial design and treatment evaluation.
One2Treat is a Belgium-based tech company specializing in integrating patient perspectives into pharmaceutical R&D decision-making. Founded in the early 2020s, the company has positioned itself as a leader in patient-centric clinical trial design and benefit-risk assessment. Its software platform helps pharmaceutical companies and researchers prioritize clinical outcomes based on patient and clinician input, aiming to improve the medical value of treatments.
One2Treat gained industry recognition in 2025 when it jointly won the Innovation award for Endpoint Design at the Clinical Trials Arena Excellence Awards with OSE Immunotherapeutics. The company launched its One2Treat Voice app in June 2025, a dedicated module for capturing and analyzing patient preferences in treatment assessments. While financial details are not publicly disclosed, One2Treat's focus on patient-centered approaches comes at a time when regulatory bodies increasingly emphasize patient-reported outcomes in drug development. The company's work spans oncology, rare diseases, and chronic conditions, with case studies demonstrating applications in breast cancer, pancreatic cancer, and non-tuberculous mycobacterial infections.
Who buys this
- Pharmaceutical companies developing new therapies
- Biotech firms conducting clinical trials
- Clinical research organizations (CROs)
- Academic medical centers running investigator-initiated trials
- Health technology assessment (HTA) bodies
Publicly disclosed clients
- OSE Immunotherapeutics
Strengths and what to watch
Strengths
- Proven methodology demonstrated in award-winning collaborations with pharma partners
- Specialized focus on patient-centric trial design in oncology and rare diseases
- Software platform with dedicated modules for different aspects of treatment assessment
Watch for
- Niche focus may limit growth as broader clinical trial tech platforms expand into patient preference tools
- Dependence on pharmaceutical R&D budgets which face pressure from industry consolidation
- Limited public information about financial performance or funding history
Recent moves
Key Information
- Founded
- 2020
Frequently Asked Questions
What does One2Treat do?
One2Treat develops software to integrate patient preferences into clinical trial design and treatment evaluation. Their platform helps pharmaceutical companies and researchers prioritize outcomes based on patient input, focusing on oncology, rare diseases, and chronic conditions. The Belgium-based company won a 2025 innovation award for endpoint design methodology.
How does One2Treat incorporate patient voices in trials?
One2Treat's software captures and analyzes patient preferences through modules like their One2Treat Voice app. This allows researchers to weigh treatment benefits against risks from the patient perspective. Their methodology has been proven in collaborations with partners like OSE Immunotherapeutics across cancer and rare disease trials.
What is the One2Treat Voice app?
Launched in June 2025, One2Treat Voice is a dedicated module for collecting patient feedback during clinical trials. The app systematically captures treatment preferences to inform trial design and drug development decisions. It represents the company's focus on patient-centered approaches in pharmaceutical R&D.
Which therapeutic areas does One2Treat specialize in?
One2Treat's case studies demonstrate applications in breast cancer, pancreatic cancer, and non-tuberculous mycobacterial infections. Their platform serves oncology, rare diseases, and chronic conditions. The software helps researchers in these areas design trials that better reflect patient priorities and real-world treatment trade-offs.
What awards has One2Treat won?
In 2025, One2Treat jointly won the Innovation Award for Endpoint Design at the Clinical Trials Arena Excellence Awards with partner OSE Immunotherapeutics. This recognized their collaborative work developing patient-centric methodologies for evaluating treatment benefits and risks in clinical development programs.
Who uses One2Treat's software?
Pharmaceutical companies, biotech firms, CROs, and academic medical centers use One2Treat's platform for trial design. Notable client OSE Immunotherapeutics collaborated on their award-winning endpoint design work. The software serves organizations needing to incorporate patient preferences into drug development and health technology assessments.
Sources
- one2treat.com — Award win with OSE Immunotherapeutics
- one2treat.com — Launch of One2Treat Voice app
- one2treat.com — Case studies in innovative trial design
- one2treat.com — Range of therapeutic areas and applications